[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"InventisBio Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":206},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,74,96,117,140,162,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100630608","phase-2-a-study-to-evaluate-d-2570-in-participants-with-moderate-to-severe-plaque-psoriasis-100630608",false,"NCT07489885","A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis","N\u002FZ","Inclusion Criteria:\n\n* Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent\n* Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.\n* Within normal ranges of laboratory assessments\n\nExclusion Criteria:\n\n* Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator","ALL","18 Years","70 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis",[28],"Psoriasis",[30],"Moderate to Severe Plaque Psoriasis","RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-22","ACTUAL",{"date":37,"type":35},"2026-06-03",{"date":39,"type":22},"2027-12",{"name":41,"class":42},"InventisBio Co., Ltd","INDUSTRY",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100640606","phase-2-a-phase-2-study-of-d-2570-in-subjects-with-non-segmental-vitiligo-100640606","NCT07625891","A Phase 2 Study of D-2570 in Subjects With Non-Segmental Vitiligo","A Phase 2 Multicenter, Randomized, Parallel-group,Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo","D2570-206","Inclusion Criteria:\n\n* Voluntarily signs informed consent and complies with study procedures.\n* Age 18-65 years, male or female.\n* Clinical diagnosis of non-segmental vitiligo at screening.\n* F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo.\n* Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose.\n\nExclusion Criteria:\n\n* \\- Segmental, mixed vitiligo or other concurrent pigmentary\u002Factive skin disorders interfering with study assessment.\n* Over 33% facial or total vitiligo lesions with leukotrichia.\n* Pregnant or breastfeeding females.\n* Active, latent or inadequately treated tuberculosis infection.\n* Positive HIV, active HBV\u002FHCV infection, or untreated syphilis.\n* Current or history of severe herpes infection.\n* Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment.\n* Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study.\n* Uncontrolled thyroid disease, severe cardiovascular\u002Fcerebrovascular disease or other unstable severe systemic disorders.\n* Severe psychiatric disease, suicidal ideation, or alcohol\u002Fdrug abuse within 6 months.\n* Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia).\n* Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing.\n* Clinically significant abnormal lab results: elevated liver\u002Frenal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts.\n* History of severe drug hypersensitivity or drug-related toxicity.\n* Any condition that may impair protocol compliance or study participation per investigator judgment.","65 Years",{"count":54,"type":22},160,[25],"This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.\n\nEligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase, where those on 27 mg or placebo will switch to one of the lower doses.\n\nAll participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.",[58,59],"Vitiligo","Non-Segmental Vitiligo (NSV)",[61,62,63],"Non-segmental Vitiligo","D-2570","Phase 2 Clinical Trial","NOT_YET_RECRUITING","2026-05-28",{"date":67,"type":35},"2026-06-04",{"date":69,"type":22},"2026-05-30",{"date":71,"type":22},"2028-05",{"name":41,"class":42},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":73},"100618068","phase-3-a-clinical-study-to-evaluate-the-efficacy-and-safety-of-d-2570-in-the-treatment-of-moderate-to-severe-plaque-psoriasis-100618068","NCT07326813","A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* The patient voluntarily participates in this study after providing fully informed consent, signs a written informed consent form, and agrees to comply with the procedures specified in the study protocol;\n* Aged between 18 and 70 years old (inclusive) at the time of signing the informed consent form, regardless of gender;\n* The investigator assesses that the subject has plaque psoriasis suitable for systemic therapy, and the condition has been stable for ≥ 6 months before signing the informed consent form;\n* At the screening stage and Day 1 (D1) of the treatment period, the Psoriasis Body Surface Area (BSA) is ≥10%, the Physician Global Assessment (PGA) score is ≥ 3 points, and the Psoriasis Area and Severity Index (PASI) score is ≥ 12 points;\n* Hematology, Blood chemistry and Urinalysis examination were basically normal;\n* Male subjects and female subjects of childbearing potential must agree to abstain from sexual intercourse or adopt effective contraceptive measures from the time of signing the informed consent form (ICF) until 30 days after the last administration of the investigational product.\n\nExclusion Criteria:\n\n* Suffering from any type of psoriasis including erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, inverse psoriasis, or drug-induced psoriasis;\n* Having other skin lesions that may interfere with the assessment of treatment outcomes, such as eczema;\n* A history of severe herpes zoster\u002Fsimplex infection;\n* A history of tuberculosis, active tuberculosis, latent tuberculosis, or clinical manifestations suggestive of tuberculosis infection\n* Having language barriers, or being unwilling or unable to fully understand and cooperate;\n* Being pregnant or lactating women;\n* Other circumstances that the investigator deems unsuitable for the subject to participate in the study.",{"count":82,"type":22},477,[84],"PHASE3","This study is a randomized, double-blind, placebo- and active-controlled multicenter clinical trial involving patients with moderate to severe plaque psoriasis.\n\nSafety and efficacy assessments will be conducted during the scheduled study visits throughout the trial. After completing the respective treatment, all subjects will undergo a safety follow-up. Both the investigators and subjects will remain blinded throughout the entire treatment period.\n\nDuring the study, subjects are required to provide blood samples for pharmacokinetic (PK) and pharmacodynamic (PD) analyses at the time points specified in the trial protocol.",[87],"Plaque Psoriasis","2026-04-23",{"date":90,"type":35},"2026-04-29",{"date":92,"type":35},"2026-01-12",{"date":94,"type":22},"2027-12-03",{"name":41,"class":42},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":73},"100616868","phase-2-a-study-of-d-2570-in-patients-with-active-systemic-lupus-erythematosus-sle-100616868","NCT07311200","A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)","A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of D-2570 in Patients With Active Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* The patient voluntarily participates in this study after full informed consent.\n* The age is 18 years ≤ age ≤ 70 years, regardless of gender.\n* Diagnosed with Systemic Lupus Erythematosus (SLE) at least ≥ 24 weeks prior to screening.\n* SLEDAI-2K total score ≥ 8.\n* On stable treatment for systemic lupus erythematosus at least 4 weeks prior to randomization, and should remain at a stable dose throughout the trial period.\n\nExclusion Criteria:\n\n* History of infection as defined in the protocol.\n* Any of the medical diseases or disorders listed in the protocol.\n* Significant, uncontrolled or unstable disease in any organ.",{"count":104,"type":22},120,[25],"This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.",[108],"Active Systemic Lupus Erythematosus",[108],{"date":111,"type":35},"2026-04-24",{"date":113,"type":35},"2026-02-12",{"date":115,"type":22},"2028-12-31",{"name":41,"class":42},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":125,"targetDuration":4,"studyType":23,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":73},"100617164","phase-2-a-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-d-2570-in-subjects-with-active-psoriatic-arthritis-100617164","NCT07315061","A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis","Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis","D2570-204","Inclusion Criteria:\n\n1. Subjects voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;\n2. Males and females, 18 to 70 years of age, inclusive at the time of signing of ICF;\n3. Have had an psoriatic arthritis of ≥ 3 months in duration prior to signing of ICF;\n4. Have had active arthritis, characterized by at least ≥3 tender joints (68 joint tenderness counts) and ≥3 swollen joints (66 joint swelling counts).\n\nExclusion Criteria:\n\n1. History of infection as defined in the protocol;\n2. Any of the medical diseases or disorders listed in the protocol;\n3. Significant, uncontrolled or unstable disease in any organ.",{"count":126,"type":22},222,[25],"This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.",[130],"PsA (Psoriatic Arthritis)",[130],"2026-04-21",{"date":134,"type":35},"2026-04-22",{"date":136,"type":35},"2026-01-16",{"date":138,"type":22},"2028-08-06",{"name":41,"class":42},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":147,"minAge":18,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":43},"100589480","phase-3-a-study-to-evaluate-d-0502-in-subjects-with-er-her2--locally-advanced-or-metastatic-breast-cancer-100589480","NCT06954961","A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer","A Randomized, Parallel-controlled, Open-label, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of D-0502 With Fulvestrant in Patients With Previously Treated ER-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer","Inclusion Criteria:\n\n* Subjects pathologically confirmed with ER-positive, HER2-negative breast cancer;\n* Subjects with locally advanced (unresectable) or metastatic breast cancer who have disease recurrence during or after adjuvant endocrine therapy, or whose disease has progressed after 1-2 lines of systemic endocrine therapy;\n* Presence of at least 1 measurable lesion that can be measured by CT or MRI based on RECIST V1.1 criteria; in the absence of measurable lesions, subjects with evaluable bone lesions \\[osteolytic or mixed (osteolytic + osteogenic) bone lesions\\] are also acceptable. Lesions that have been previously treated with radiotherapy or other local therapy can be regarded as measurable lesions only if there is disease progression as confirmed by imaging examination;\n* Expected survival time ≥ 12 weeks;\n\nExclusion Criteria:\n\n* Subjects with unstable or symptomatic or progressive central nervous system (CNS) metastases. Subjects with a history of brain metastases who are clinically stable and have no CNS disease progression confirmed by brain MRI or CT (if MRI is not appropriate) can be enrolled (MRI or CT examination must be conducted at least 4 weeks after the last brain radiotherapy);\n* Subjects with locally advanced or metastatic breast cancer who have previously received more than 2 prior systemic chemotherapy;\n* Subjects are unsuitable for endocrine therapy judged by the investigator, including uncontrolled pleural effusion, ascites or pericardial effusion;\n* Subjects with concomitant medical conditions that the investigator believes may increase the risk of toxicity, such as serious cardiovascular, respiratory or neurological diseases;\n* Prior treatment with a selective estrogen receptor degrader (SERD)\u002Fselective estrogen receptor covalent antagonist (SERCA), such as fulvestrant, GDC-9545, AZD9833, SAR-439859, Zn -c5, LX-039, HS234, etc.;\n* Pregnant or lactating females;","FEMALE","75 Years",{"count":150,"type":22},640,[84],"This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.",[154],"Breast Cancer","2026-03-25",{"date":157,"type":35},"2026-03-31",{"date":159,"type":35},"2022-09-15",{"date":115,"type":22},{"name":41,"class":42},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":73},"100602983","phase-3-evaluate-the-efficacy-and-safety-of-d-2570-in-subjects-with-moderate-to-severe-plaque-psoriasis-100602983","NCT07130604","Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n1. Subject voluntarily takes part in the study after being fully informed,signs a written ICF, and agrees to follow procedures specified in the study protocol;\n2. Plaque psoriasis assessed by the investigator as suitable for systemic treatment and stable (defined as stable as no significant outbreak of morphological change or disease activity assessed by the investigator) for at least 6 months prior to signing informed consent;\n3. During the screening period and before taking the investigational drug for the first time, psoriatic surface area (BSA) ≥10%, PGA score ≥ 3, PASI score ≥ 12;\n4. Hematology, Blood chemistry and Urinalysis examination were basically normal.\n\nExclusion Criteria:\n\n1. Erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, reverse psoriasis, drug-induced psoriasis;\n2. Have other skin lesions that affect the evaluation of treatment outcomes, such as eczema;\n3. History of herpes zoster\u002Fherpes simplex, or presence of herpes zoster\u002Fherpes simplex infection during the screening period;\n4. Have a history of tuberculosis, or active tuberculosis, or latent tuberculosis, or suspected clinical manifestations of tuberculosis infection;\n5. Other conditions that the investigator considers inappropriate for participation in the study.",{"count":170,"type":22},390,[84],"This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis.",[87],"2025-12-07",{"date":176,"type":35},"2025-12-09",{"date":178,"type":35},"2025-09-18",{"date":180,"type":22},"2027-07-28",{"name":41,"class":42},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":191,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":73},"100595637","phase-2-a-phase-2-study-of-d-2570-in-subjects-with-moderately-to-severely-active-ulcerative-colitis-100595637","NCT07035041","A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis","A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 as Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis","D2570-202","Inclusion Criteria:\n\nSubjects who meet all of the following criteria can be included in this study:\n\n1. Subjects voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;\n2. Males and females, 18 to 70 years of age, inclusive at the time of signing of ICF;\n3. Have had an established diagnosis of ulcerative colitis (UC) of ≥ 3 months in duration prior to signing of ICF, which is supported by endoscopy reports, histopathology reports and clinical manifestations consistent with UC, as determined by investigators;\n4. Involved intestinal segment extending ≥ 15 cm from the anal verge as confirmed by a screening endoscopy;\n5. Active moderate to severe UC, defined by a modified Mayo score of 5 to 9 points at screening, which includes a stool frequency (SF) subscore of ≥ 2, a rectal bleeding (RB) subscore ≥ 1 and an endoscopic (ES) subscore of ≥ 2 (based on a screening endoscopy, confirmed by central reading);\n6. Documentation of an inadequate response, loss of response, or intolerance (defined as interruption of drug due to an adverse reaction as evaluated by the investigator) to a treatment course of 1 or more of the following standard of care medications:\n7. If a subject is using oral 5-ASAs, and\u002For oral glucocorticoids (≤ 20 mg\u002Fday of prednisone or equivalent dose, or ≤ 9 mg\u002Fday of budesonide or equivalent dose), and\u002For probiotics to treat UC, the dosage must remain stable for ≥ 2 weeks prior to the screening endoscopy and during the study period;\n8. If 5-ASAs and glucocorticoids have already been discontinued, they must have been discontinued for ≥ 2 weeks prior to the screening endoscopy;\n\n   * Exclusion Criteria\n\nSubjects cannot be included in the study if any of the following exclusion criteria is met:\n\n1. Diagnosed or suspected Crohn's disease, indeterminate colitis, fulminant colitis, toxic megacolon, microscopic colitis, ischemic colitis, radiation colitis, or colitis associated with diverticula;\n2. History of colonic resection, subtotal or total colectomy, or surgical intervention for UC, or anticipated need for, as assessed by the investigator, surgical intervention for UC during the study, or with other gastrointestinal diseases or surgical histories that may affect the absorption of study treatment;\n3. Current gastrointestinal dysplasia or past confirmed gastrointestinal dysplasia that has not been eradicated; For subjects diagnosed with UC for more than 8 years, a colonoscopy to screen for dysplasia should have been performed within 1 year prior to randomization or may be conducted during the screening colonoscopy.\n\n   Subjects with a history of adenomatous polyps are eligible if the polyps have been completely removed (as documented in the medical records), and no residual polyps or evidence of dysplasia is found in the colonoscopy and histological examination at screening.\n4. Previous history of serious herpes zoster\u002Fherpes simplex infection, including but not limited to disseminated herpes simplex\u002Fherpes zoster infection, generalized herpes zoster, herpetic encephalitis\u002Fmeningitis, ocular herpes, recurrent herpes zoster, or other serious herpes zoster\u002Fherpes simplex infections assessed by the investigator, or presence of herpes zoster\u002Fherpes simplex infection at screening;\n5. History of tuberculosis, active tuberculosis, latent tuberculosis, or clinical manifestations suggestive of tuberculosis infection; for subjects with latent tuberculosis infection (i.e., tested positive interferon-gamma release assay \\[IGRA\\] for Mycobacterium tuberculosis at screening) but without any symptoms, signs, laboratory findings, or imaging evidence of tuberculosis infection, re-screening is allowed after completing at least 4 weeks of standard preventive anti-tuberculosis treatment and evaluation by the investigator; subjects with indeterminate IGRA results must undergo a repeat test for confirmation, if the second test result is also indeterminate, the subject will be excluded from the study;\n6. Test positive for human immunodeficiency virus (HIV) antibody, or syphilis antibody (that is the subject develops an active or latent syphilis infection), or positive for hepatitis C virus (HCV) antibody and hepatitis C virus ribonucleic acid (HCV RNA) test or a viral load greater than the upper limit of normal at the study site, or positive for hepatitis B surface antigen (HBsAg). For subjects who are HBsAg-negative but positive for hepatitis B core antibody (HBcAb), further hepatitis B virus deoxyribonucleic acid (HBV DNA) test is required. If HBV DNA is tested positive or the viral load exceeds the upper limit of normal at the study site, they will also be excluded;\n7. Previous administration of a live vaccine within 3 months or an inactivated vaccine within 30 days prior to randomization, or planning to administer a live vaccine during the study or within 1 month after the last dose of investigational product;\n8. Have undergone a major surgery within 8 weeks prior to randomization, or planning to undergo any surgery during the study, unless the investigator determines that the surgery will not increase the subject's risk or affect his\u002Fher ability to receive study treatment and comply with the study requirements;\n9. History of a serious viral, bacterial, or fungal infection which requires intravenous (IV) anti-infectives, or hospitalization for treatment within 3 months prior to randomization, or develops a viral, bacterial, or fungal infection which requires antibiotics\u002Fanti-viral treatment within 2 weeks prior to randomization;\n10. History of stool positive for C. difficile test or evidence for other enteric pathogen infections within 3 months prior to randomization or at screening. Subjects may be re-screened 30 days after completion of a standard of care course with anti-infectives, and subsequent negative testing for corresponding tests and no persistent symptoms of infection with the pathogen, upon evaluation by the investigator;",{"count":104,"type":22},[25],"This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with moderately to severely active ulcerative colitis. A total of 120 subjects are planned to be included.",[194,195],"UC - Ulcerative Colitis","Moderately to Severely Active Ulcerative Colitis",[195,197],"UC","2025-06-16",{"date":200,"type":35},"2025-06-24",{"date":202,"type":35},"2025-05-22",{"date":204,"type":22},"2026-12-31",{"name":41,"class":42},""]